Brief: Hoth Therapeutics Plans To Advance HT-ALZ Into Clinical Development
02/04/2025 12:59
April 2 (Reuters) - Hoth Therapeutics Inc HOTH.O: HOTH THERAPEUTICS ANNOUNCES POSITIVE PRE CLINICAL DATA HT-ALZ SHOWS PROMISING BREAKTHROUGH IN ALZHEIMER'S DISEASE RESEARCH ACUTE TREATMENT WITH HT-ALZ LED TO A RAPID (~15%) REDUCTION IN BRAIN INTERSTITIAL FLUID AΒ LEVELS, WITHIN 20 HOURS HOTH THERAPEUTICS - PLANS TO ADVANCE HT-ALZ INTO CLINICAL DEVELOPMENT Source text: ID:nPnbTk1V8a Further company coverage: HOTH.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Rocket One
See all newsBrief: Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Brief: Rocket One Signs Agreement To Advance Nanomagnetic Ai Chip Technology And Device Prototyping
Brief: Rocket One Signs Patent License Agreement With U.S. Air Force For Technology Designed To Capture And Neutralize Hostile Drones
Brief: Rocket One To Buy 100% Ownership Of Tracer Drone Technologies
Brief: Rocket One And Nasa Reach Agreement To Advance Space Ai Technology